Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Initial clinical data highlight a differentiated safety and pharmacologic profile for PHST001, including target engagement, innate immune activation, and early signals of clinical activity ...
-
Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable...
-
Asgard Therapeutics to present a poster on its lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026.
-
STORM Therapeutics announces a $56 million Series C financing to support the advancement of STC-15 in a Phase 2 study.
-
Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in...
-
Manufacturing Agreement Advances Metformin Ophthalmology Platform Toward First-in-Human Clinical Study Palm Beach Gardens, FL, April 15, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC:...
-
Major paradigm shift incorporates five-year risk assessment and identifies increased-risk women beginning at age 35 BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Clairity, Inc. announces the National...
-
GeneCentric will present new data on its fragmentomics-based ExpressCT™ liquid biopsy technology at AACR 2026.
-
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
-
OSS, The Netherlands, April 14, 2026 (GLOBE NEWSWIRE) -- Trained Therapeutix Discovery, a biotechnology company founded by the Jean Boulle Group and the Heritage Group, today announced that its...